We thus hypothesized that the oncogenic potential of this mutation may need a particular cancer context, such as the presence of acquired mutation in key genes for GBM development (EGFR, PTEN, TP53, NF1, and IDH1), as no previous study defined P336L as a driver mutation. This evidence concerns the gene EGFR and cancer.